Hormonal
Perilipin 1 (PLIN1) acts as a gatekeeper for lipid storage by sequestering lipases (ATGL and HSL) from cytosolic lipid droplets in the basal state, thereby suppressing lipolysis until hormonal stimulation triggers phosphorylation and enzyme recruitment.
In fat cells, a protein called PLIN1 acts as a protective coat that keeps fat-burning enzymes away from stored fat when you are at rest or fed. This prevents unnecessary fat loss. Only when your body signals a need for energy (via hormones like adrenaline) does this coat get modified to allow enzymes access. This highlights that fat storage is an active, regulated process, not just passive accumulation.
Under basal (e.g., fed or insulin-stimulated) conditions for WAT, CLD-bound Plin1a is unphosphorylated, and the two major lipolytic enzymes, ATGL (adipose triacylglycerol lipase) and HSL, are cytosolic... Thus, under basal conditions, lipases are sequestered from CLDs and lipolysis is suppressed.
Why this rating
Based on extensive genetic knockout studies (Plin1-/- mice) and molecular characterization.
Source
The Perilipins: Major Cytosolic Lipid Droplet–Associated Proteins and Their Roles in Cellular Lipid Storage, Mobilization, and Systemic Homeostasis
Alan R. Kimmel et al. · Annual Review of Nutrition · 2016
DOI 10.1146/annurev-nutr-071813-105410
More from this paper
- Defective lipid storage capacity in white adipose tissue, often due to impaired expansion or PLIN dysfunction, leads to ectopic fat deposition in non-adipose tissues, causing insulin resistance and type 2 diabetes.Strong
- PLIN2 and PLIN3 regulate lipid droplet hydrolysis in non-adipose tissues but are less effective barriers against lipases than PLIN1, and do not compensate for PLIN1 loss in white adipose tissue.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →